SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-1.32%18.762.0%$166.39m
ICPTIntercept Pharmaceuticals, Inc.
1.82%115.1518.6%$161.00m
JAZZJazz Pharmaceuticals Plc
1.84%136.032.3%$110.58m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.29%176.006.3%$94.31m
SAGESAGE Therapeutics, Inc.
3.62%157.988.8%$90.34m
HZNPHorizon Pharma plc
0.11%27.917.3%$86.93m
PRGOPerrigo Co. Plc
0.39%48.546.8%$68.17m
ICLRICON Plc
0.06%136.754.1%$58.96m
MNKMallinckrodt Plc
0.59%23.8021.0%$55.65m
UTHRUnited Therapeutics Corporation
1.44%122.9914.3%$55.20m
PTLAPortola Pharmaceuticals, Inc.
2.13%33.637.6%$45.58m
AERIAerie Pharmaceuticals, Inc.
7.39%49.256.9%$41.81m
MYOKMyoKardia, Inc.
2.42%55.822.4%$37.75m
ENDPEndo International Plc
0.34%8.768.9%$37.73m
MDCOMedicines Company
3.59%28.0221.8%$30.85m

Company Profile

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.